AUTHOR=Troullioud Lucas Alexandre G. , Boelens Jaap Jan , Prockop Susan E. , Curran Kevin J. , Bresters Dorine , Kollen Wouter , Versluys Birgitta , Bierings Marc B. , Archer Anne , Davis Eric , Klein Elizabeth , Kernan Nancy A. , Lindemans Caroline A. , Scaradavou Andromachi 

TITLE=Excellent leukemia control after second hematopoietic cell transplants with unrelated cord blood grafts for post-transplant relapse in pediatric patients

JOURNAL=Frontiers in Oncology

VOLUME=Volume 13 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1221782

DOI=10.3389/fonc.2023.1221782

ISSN=2234-943X

ABSTRACT=Background: Patients with leukemia relapse after allogeneic hematopoietic cell transplant (HCT) have poor survival due to toxicity and disease progression. A second HCT often offers the only curative treatment.We retrospectively reviewed our bi-institutional experience (MSKCC-USA; Utrecht-NL) with unrelated cord blood transplantation (CBT) for treatment of post-transplant relapse. Overall survival (OS) and Event-Free Survival (EFS) were evaluated using the Kaplan-Meier method, treatment-related mortality (TRM) and relapse were evaluated using the competing risk method by Fine-Gray.Results: Twenty-six patients age < 21 years received a second (n=24) or third (n=2) HCT with CB grafts during the period 2009-2021. Median age at first HCT (HCT1) was 11.5 (range: 0.9-17.7) years and all patients received myeloablative cytoreduction. Median time from HCT1 to relapse was 12.8 (range 5.5-189) months.